Oral gatifloxacin in outpatient community-acquired pneumonia: Results from TeqCES, a community-based, open-label, multicenter study

Diagnostic Microbiology and Infectious Disease

Volumn 44, Issue 1, 2002, Pages 85-91

  Gotfried, Mark ^a   Quinn, Thomas C ^b   Gothelf, Samantha ^c   Wikler, Matthew A ^d   Webb, C Douglas ^c   Nicholson, Susan C ^c,e  

^a Pulmonary Associates   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d ViroPharm Incorporated   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Community acquired pneumonia; Gatifloxacin; TeqCES

Indexed keywords

8 METHOXYFLUOROQUINOLONE; ANTIINFECTIVE AGENT; BETA LACTAMASE; GATIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENZYME SYNTHESIS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; PENICILLIN RESISTANCE; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; RADIOGRAPHY; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0036743891     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(02)00447-9     Document Type: Article

References (25)

1. Ambrose P.G., Owens R.C. Jr. New antibiotics in pulmonary and critical care medicine focus on advanced generation quinolones and cephalosporins . Seminars Respiratory Critical Care Medicine. 21:2000;19-32.
2. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. New England Journal of Medicine. 333:1995;1618-1624.
3. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr, Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clinical Infectious Disease. 31:2000;347-382.
4. Blondeau J.M. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones.'. Journal of Antimicrobial Chemotherapy. 43:(Suppl. B):1999;1-11.
5. Breen J., Skuba K., Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. Journal of Respiratory Disease. 20:(Suppl. 11):1999;S70-S76.
6. File T.M., Tan J.S. Incidence, etiologic patterns, and diagnostic testing of community-acquired pneumonia. Current Opinions in Pulmonary Medicine. 3:1997;89-97.
7. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., Coley C.M., Marrie T.J., Kapoor W.N. A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine. 336:1997;243-250.
8. Fung-Tomc J., Minassian B., Kolek B., Washo T., Huczko E., Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. Journal of Antimicrobial Chemotherapy. 45:2000;437-446.
9. Gotfried M. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting results from the 1999-2000 Respiratory Surveillance Program (RESP) . American Journal of Medicine. 111:(Suppl. 1):2001;19-24.
10. Grasela D.M. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clinical Infectious Disease. 31:(Suppl. 2):2000;S51-S58.
11. Huczko E., Conetta B., Bonner D., Valera L., Stickle T., Macko A., Fung-Tomc J. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998. International Journal of Antimicrobial Agents. 6:2000;401-405.
12. Hyde T.B., Gay K., Stephens D.S., Vugia D.J., Pass M., Johnson S., Barrett N.L., Schaffner W., Cieslak P.R., Maupin P.S., Zell E.R., Jorgensen J.H., Facklam R.R., Whitney C.G., for the Active Bacterial Core Surveillance/Emerging Infections Program Network . Macrolide resistance among invasive Streptococcus pneumoniae isolates. Journal of the American Medical Association. 286:2001;1857-1862.
13. Jones R.N., Pfaller M.A. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance data from the SENTRY Antimicrobial Surveillance Program . Clinical Infectious Disease. 31:(Suppl. 2):2000;S16-S23.
14. Mandell L.A. Community-acquired pneumonia. Etiology, epidemiology, and treatment. Chest. 108:(Suppl.):1995;35S-42S.
15. Mandell L.A., Marrie T.J., Grossman R.F., Chow A.W., Hyland R.H., the Canadian Community-Acquired Pneumonia Working Group . Canadian guidelines for the initial management of community-acquired pneumonia an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society . Clinical Infectious Disease. 31:2000;383-421.
16. National Committee for Clinical Laboratory Standards . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard M7-A5. 5th ed. 2000;NCCLS, Wayne, PA.
17. National Committee for Clinical Laboratory Standards . Performance standards for antimicrobial susceptibility testing, tenth informational supplement M100-S10. 2000;NCCLS, Wayne, PA.
18. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., Dean N., File T., Fine M.J., Gross P.A., Martinez F., Marrie T.J., Plouffe J.F., Ramirez J., Sarosi G.H., Torres A., Wilson R., Yu V.L. Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention . American Journal of Respiratory Critical Care Medicine. 163:2001;1730-1754.
19. Plouffe J.F. Importance of atypical pathogens of community-acquired pneumonia. Clinical Infectious Disease. 31:(Suppl. 2):2000;S35-S39.
20. Ramirez J.A., Nguyen T.-H., Tellier G., Coppola G., Bettis R.B., Dolmann A., St.-Pierre C., Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. Journal of Respiratory Disease. 20:(Suppl. 11):1999;S40-S48.
21. Schentag J.J. Clinical pharmacology of the fluoroquinolones studies in human dynamic/kinetic models . Clinical Infectious Disease. 31:(Suppl. 2):2000;S40-S44.
22. Sullivan J.G., McElroy A.D., Honsinger R.W., McAdoo M., Harrison B.J., Plouffe J.F., Gotfried M., Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin. Journal of Respiratory Disease. 20:(Suppl. 11):1999;S49-S59.
23. Von Seggern K., Russo R., Wikler M.A. A novel approach to postmarketing surveillance the Tequin Clinical Experience Study . Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 468:2000;American Society for Microbiology, Washington, D. C. Abstract 2216.
24. Zhao X., Xu C., Domagala J., Drlica K. DNA topoisomerase targets of the fluoroquinolones a strategy for avoiding bacterial resistance . Proceedings of the National Academy of Science USA. 94:1997;13991-13996.
25. Zhao X., Wang J.-Y., Xu C., Dong Y., Zhou J., Domagala J., Drlica K. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrobial Agents and Chemotherapy. 42:1998;956-958.